BLUNDELL, SANDRA,KERAMIDAS, PANAGIOTIS,MOONEY, BRETT ANTONY,RUTHERFORD, TODD JAMES
申请号：
ES08706056
公开号：
ES2522297T3
申请日:
2008.02.11
申请国别(地区):
ES
年份:
2014
代理人:
摘要：
A pharmaceutical form for the administration of two pharmaceutical active ingredients to a subject, comprising a first pharmaceutical composition comprising a first pharmaceutical active ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of a form powder, granules, pildorites, microspheres or mini-tablets and a second pharmaceutical composition comprising a second pharmaceutical active ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of a form in granules, pildorites, microspheres , mini-tablets or tablets, wherein said first pharmaceutical active ingredient is fluoxetine or a pharmaceutically acceptable salt thereof and said second pharmaceutical active ingredient is olanzapine or a pharmaceutically acceptable salt thereof, and wherein said first and s Second physical forms are selected to be different to minimize the interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis based on the difference in size.Una forma farmacéutica para la administración de dos principios activos farmacéuticos a un sujeto, que comprende una primera composición farmacéutica que comprende un primer principio activo farmacéutico y opcionalmente uno o más excipientes farmacéuticamente aceptables en una primera forma física seleccionada a partir del grupo constituido por una forma en polvo, gránulos, pildoritas, microesferas o minicomprimidos y una segunda composición farmacéutica que comprende un segundo principio activo farmacéutico y opcionalmente uno o más excipientes farmacéuticamente aceptables en una segunda forma física seleccionada a partir del grupo constituido por una forma en gránulos, pildoritas, microesferas, minicomprimidos o comprimidos, donde dicho primer principio activo farmacéutico es fluoxetina o
